GSK - Vir Biotechnology: Expanded Hepatitis Pipeline And COVID-19 Revenue Expected

• Vir Biotechnology had obtained about $917.2 million of sotrovimab collaboration revenue in 2021; Expects about $1.1 billion in revenues with all doses delivered by 1st half of 2022.
• About 95% of patients who took VIR-2218 plus PEG-IFN-a achieved Hepatitis B surface antigen ((HBsAg)) levels < 100 IU/mL.
• Expansion of pipeline moving towards the targeting of Hepatitis Delta Virus whereby both VIR-2218 and VIR-3434 will be tested against it.
• The global Hepatitis B Virus market is expected to reach $35.63 billion in 2030.
• Combination of VIR-2218 and VIR-3434 also being tested for the treatment of patients with Hepatitis B in a phase 2 study; results from this study expected by 2nd half of 2023.

For further details see: